A Multicenter Open-label Study of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics After Dose Escalation in Japanese Subjects With Crohn's Disease
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 20 Jun 2016 Results published in an Eisai media release.
- 20 Jun 2016 According to an Eisai media release, the company has announced additional approval for a new dosing regimen of Humira pre-filled syringe 40 mg/0.8 mL for subcutaneous injection (adalimumab [recombinant]) in patients with moderate or severe Crohn's disease.
- 08 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.